Novel anti-angiogenic agents such as vanucizumab, which simultaneously inhibits VEGF-A and angiopoietin-2 (Ang-2), thereby significantly reducing abnormal tumor angiogenesis [253]. Here, ANGPT2 is linked to neoplasm.